( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



Jyoti Kaushal, Dhiren M Pranami*, Sanjiv Nanda, Madhu Sharma


Objectives: This study aimed to compare the efficacy and safety of piperacillin/tazobactam plus amikacin versus ceftriaxone plus amikacin for treating complicated pneumonias in children. Materials and Methods: A prospective, randomized, comparative, open label & parallel study was done on 40 children of either sex and age between 2 to 14 years having complicated pneumonia.They were randomly allocated with the help of computer generated random numbers to receive either piperacillin/tazobactam plus amikacin(PTA group) or ceftriaxone plus amikacin(CA group). Efficacy assessment was done by observing sign and symptoms of pneumonia i.e fever, cough (productive or non-productive), dyspnoea, chest pain etc. & laboratory investigations like chest X-ray & pleural fluid examination. The number of days patients were hospitalized, was noted and a record was maintained. The number of patients who required oxygen inhalation and needed mechanical ventilation, was also noted. Safety assessment was done by observing the side effects of antibiotic therapy. Results: Duration of fever in PTA group was 3.70 ± 0.46 days while in CA group it was 5.30 ± 0.51 days. This difference was statistically significant (p < 0.05). Duration of hospital stay in PTA group was 12.00 ± 0.95 days and in CA group was 14.70 ± 0.70 days and this difference was statistically significant with the p value of 0.028. Sixteen (80%) patients in PTA group were cured whereas in CA group thirteen (65%) patients were cured. Regarding the therapeutic success of medication, no statistically significant difference was observed between the two groups, although more patients were cured and less had failure with treatment in PTA group as compared to CA group. Both the treatment regimens were well tolerated with minor ADRs. Conclusions : Both the treatment groups i.e. piperacillin/tazobactam plus amikacin (PTA) and ceftriaxone plus amikacin (CA) were found to be safe & efficacious in management of complicated pneumonia in children. On comparing the above mentioned treatment groups, better response was observed in PTA as compared to CA group.

Keywords: Childhood Pneumonias, Complicated Pneumonias, Piperacillin/Tazobactam, Ceftriaxone, Amikacin.

[Full Text Article]



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2021 Issue has been Published, Kindly check it on


    NOVEMBER Issue has been successfully launched on 1 November 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )